TY - JOUR AU - Caravaca-Fontan, Fernando AU - Diaz-Encarnacion, Montserrat M AU - Lucientes, Laura AU - Cavero, Teresa AU - Cabello, Virginia AU - Ariceta, Gema AU - Quintana, Luis F AU - Marco, Helena AU - Barros, Xoana AU - Ramos, Natalia AU - Rodriguez-Mendiola, Nuria AU - Cruz, Sonia AU - Fernandez-Juarez, Gema AU - Rodriguez, Adela AU - Perez de Jose, Ana AU - Rabasco, Cristina AU - Rodado, Raquel AU - Fernandez, Loreto AU - Perez Gomez, Vanessa AU - Avila, Ana I AU - Bravo, Luis AU - Lumbreras, Javier AU - Allende, Natalia AU - Sanchez de la Nieta, Maria Dolores AU - Rodriguez, Eva AU - Olea, Teresa AU - Melgosa, Marta AU - Huerta, Ana AU - Miquel, Rosa AU - Mon, Carmen AU - Fraga, Gloria AU - de Lorenzo, Alberto AU - Draibe, Juliana AU - Cano-Megias, Marta AU - Gonzalez, Fayna AU - Shabaka, Amir AU - Lopez-Rubio, Maria Esperanza AU - Fenollosa, Maria Angeles AU - Martin-Penagos, Luis AU - Da Silva, Iara AU - Alonso Titos, Juana AU - Rodriguez de Cordoba, Santiago AU - Goicoechea de Jorge, Elena AU - Praga, Manuel PY - 2020 DO - 10.2215/CJN.15241219 UR - http://hdl.handle.net/10668/16118 T2 - Clinical journal of the American Society of Nephrology : CJASN AB - C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was... LA - en PB - American Society of Nephrology KW - Alternative complement pathway KW - C3 glomerulopathy KW - Mycophenolate mofetil KW - Adolescent KW - Adrenal Cortex Hormones KW - Adult KW - Child KW - Complement C3 KW - Disease Progression KW - Drug Therapy, Combination KW - Female KW - Glomerulonephritis KW - Humans KW - Immunosuppressive Agents KW - Male KW - Middle Aged KW - Mycophenolic Acid KW - Recurrence KW - Remission Induction KW - Retrospective Studies KW - Risk Factors KW - Spain KW - Time Factors KW - Treatment Outcome KW - Young Adult TI - Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. TY - research article VL - 15 ER -